{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:22:22Z","timestamp":1787156542090,"version":"build-2736575974"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004577","name":"Kementerian Pertanian dan Industri Asas Tani Malaysia","doi-asserted-by":"publisher","award":["HRGS\/ NH1015S017"],"award-info":[{"award-number":["HRGS\/ NH1015S017"]}],"id":[{"id":"10.13039\/501100004577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pupt.2025.102375","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T11:44:33Z","timestamp":1750333473000},"page":"102375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The era of multiple biologics: Is combination and switching an option in the management of severe asthma?"],"prefix":"10.1016","volume":"90","author":[{"given":"Emmanuel Oshiogwe","family":"Okwuofu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey Chee Hui","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Chee Woei","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson","family":"Stanslas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2025.102375_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060160","article-title":"Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France","volume":"12","author":"Roche","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.pupt.2025.102375_bib3","first-page":"847","article-title":"Severe asthma: definition, diagnosis and treatment","volume":"111","author":"Lommatzsch","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.pupt.2025.102375_bib4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13223-022-00676-0","article-title":"The new era of add-on asthma treatments: where do we stand?","volume":"18","author":"Calhoun","year":"2022","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.pupt.2025.102375_bib5","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1007\/s12325-023-02659-y","article-title":"Effect of tezepelumab on lung function in patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study","volume":"40","author":"Menzies-Gow","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.pupt.2025.102375_bib6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.pupt.2025.102375_bib7","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2025.102375_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2025.102375_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00309-2020","article-title":"Identification and treatment of T2-low asthma in the era of biologics","volume":"7","author":"Kyriakopoulos","year":"2021","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.pupt.2025.102375_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13601-019-0303-6","article-title":"Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper","volume":"10","author":"Hox","year":"2020","journal-title":"Clin. Transl. Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-023-02439-w","article-title":"Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study","volume":"24","author":"Vultaggio","year":"2023","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2025.102375_bib12","first-page":"1","article-title":"Anti-IL-5\/5Ra biologics improve work productivity and activity in severe asthma: a RAPSODI registry-based cohort study","author":"van der Valk","year":"2023","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2025.102375_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107058","article-title":"Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: a real-world Dutch cohort study","volume":"206","author":"Thelen","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI biologicals guidelines-recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.anai.2021.08.416","article-title":"Asthma biologics: real-world effectiveness, impact of switching biologics, and predictors of response","volume":"127","author":"Abbas","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.pupt.2025.102375_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100737","article-title":"Risks and safety of biologics: a practical guide for allergists","volume":"16","author":"Sitek","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.pupt.2025.102375_bib17","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/JAA.S340684","article-title":"Feasibility of discontinuing biologics in severe asthma: an algorithmic approach","volume":"14","author":"Hamada","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2025.102375_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00586-2022","article-title":"Characteristics of severe asthma patients on biologics: a real-life European registry study","volume":"9","author":"Principe","year":"2023","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.pupt.2025.102375_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/cea.14222","article-title":"Biologic therapy practices in severe asthma; outcomes from the UK severe asthma registry and survey of specialist opinion","volume":"53","author":"Mansur","year":"2022","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/JAA.S363398","article-title":"Efficacy and safety of omalizumab treatment over a 16-Year follow-up: when a clinical trial meets real-life","volume":"15","author":"Menzella","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17534666231170821","article-title":"Role of clinical biomarkers in predicting the effectiveness of omalizumab","volume":"17","author":"Zhang","year":"2023","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.pupt.2025.102375_bib23","article-title":"Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: an ANANKE study post hoc analysis","volume":"9","author":"Caruso","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.pupt.2025.102375_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000534319","article-title":"Omalizumab transitions in severe asthma: factors influencing switching decisions and timing for optimal response","volume":"32","author":"Al-Ahmad","year":"2023","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.pupt.2025.102375_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2147\/JAA.S403286","article-title":"Real-world experience on the use of mepolizumab from the severe asthma registry of the German asthma net (MepoGAN-Study)","volume":"16","author":"Korn","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.5507\/bp.2023.029","article-title":"Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia","volume":"167","author":"Jesenak","year":"2023","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub."},{"key":"10.1016\/j.pupt.2025.102375_bib27","article-title":"Real-world clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab","volume":"3","author":"Walsh","year":"2022","journal-title":"Front. Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101899","article-title":"Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life","volume":"61","author":"Sposato","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2025.102375_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106491","article-title":"Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study","volume":"185","author":"Crimi","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"ChAracterization of ItaliaN severe uncontrolled asthmatic patieNts key features when receiving benralizumab in a real-life setting: the observational rEtrospective ANANKE study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2025.102375_bib31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2147\/JAA.S358705","article-title":"Effectiveness of switching to benralizumab in severe refractory eosinophilic asthma","volume":"15","author":"G\u00f3mez-Bastero Fern\u00e1ndez","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib32","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2169\/internalmedicine.8180-21","article-title":"Switching treatment from mepolizumab to benralizumab for elderly patients with severe eosinophilic asthma: a retrospective observational study","volume":"61","author":"Isoyama","year":"2022","journal-title":"Intern. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051836","article-title":"Benralizumab efficacy in late non-responders to mepolizumab and variables associated with occurrence of switching: a real-word perspective","volume":"12","author":"Caminati","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134362","article-title":"Benralizumab in patients with severe eosinophilic asthma: a multicentre real-life experience","volume":"12","author":"Scioscia","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2022.04.014","article-title":"Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma - first initiators and switchers","volume":"10","author":"Hashimoto","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2025.102375_bib36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1164\/rccm.201708-1668OC","article-title":"Predicting responders to reslizumab after 16 weeks of treatment using an algorithm derived from clinical studies of patients with severe eosinophilic asthma","volume":"199","author":"Bateman","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2025.102375_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.01.017","article-title":"Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: a multicenter, open-label pilot study","volume":"7","author":"P\u00e9rez de Llano","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2025.102375_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/JAA.S312123","article-title":"Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program","volume":"14","author":"Campisi","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib39","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.alit.2023.04.001","article-title":"Real-world impact of dupilumab on asthma disease burden in Japan: the CROSSROAD study","volume":"72","author":"Fukunaga","year":"2023","journal-title":"Allergol. Int."},{"key":"10.1016\/j.pupt.2025.102375_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/JAA.S357548","article-title":"Real-world effectiveness of dupilumab for patients with severe asthma: a retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/iid3.434","article-title":"Dupilumab rapidly improves asthma control in predominantly anti-IL5\/IL5R pretreated Austrian real-life severe asthmatics","volume":"9","author":"Renner","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.pupt.2025.102375_bib43","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jaip.2024.05.052","article-title":"Real-world data on tezepelumab in patients with severe asthma in Germany","volume":"12","author":"Biener","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2025.102375_bib44","first-page":"1","article-title":"Early response to tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study","author":"Jim\u00e9nez-G\u00f3mez","year":"2024","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2025.102375_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221133689","article-title":"Comparison between clinical trials and real-world evidence studies on biologics for severe asthma","volume":"50","author":"Menzella","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.pupt.2025.102375_bib46","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","article-title":"Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making","volume":"19","author":"Otten","year":"2023","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.pupt.2025.102375_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620929231","article-title":"Switching from omalizumab to mepolizumab: real-life experience from southern Italy","volume":"14","author":"Carpagnano","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.pupt.2025.102375_bib48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100707","article-title":"Combining biologics targeting eosinophils (IL-5\/IL-5R), IgE, and IL-4\/IL-13 in allergic and inflammatory diseases","volume":"15","author":"Pitlick","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.pupt.2025.102375_bib50","first-page":"1","article-title":"Eff\u0131cacy of mepol\u0131zumab and omal\u0131zumab comb\u0131nat\u0131on therapy in uncontrolled asthma","author":"Sezgin","year":"2023","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2025.102375_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242211","article-title":"Dual biologic therapy in a patient with severe asthma and other allergic disorders","volume":"14","author":"Caskey","year":"2021","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.pupt.2025.102375_bib52","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1080\/02770903.2022.2109162","article-title":"Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study","volume":"60","author":"Baccelli","year":"2023","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2025.102375_bib53","first-page":"306","article-title":"Combination Anti-IgE and Anti-IL5 therapy in a pediatric patient with severe persistent asthma","volume":"26","author":"Fox","year":"2021","journal-title":"J. Pediatr. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2025.102375_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1266","article-title":"Dual biologics for severe asthma and atopic dermatitis: synopsis of two cases and literature review","volume":"12","author":"Matsumoto","year":"2024","journal-title":"Respirol. Case Rep."},{"key":"10.1016\/j.pupt.2025.102375_bib55","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/ajd.13676","article-title":"Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma","volume":"62","author":"Mahar","year":"2021","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.pupt.2025.102375_bib56","article-title":"Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series","volume":"7","author":"Malik","year":"2023","journal-title":"Rheumatol. Adv. Pract."},{"key":"10.1016\/j.pupt.2025.102375_bib57","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/02770903.2023.2260884","article-title":"Dual biologics therapy in a patient with severe asthma and chronic urticaria: a case report and review of the literature","volume":"61","author":"Can Bostan","year":"2024","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2025.102375_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/02770903.2023.2244590","article-title":"Efficacy of mepolizumab and omalizumab combination therapy in uncontrolled asthma","volume":"61","author":"Sezgin","year":"2024","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2025.102375_bib59","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/JAA.S348513","article-title":"Clinical characteristics of patients and factors associated with switching biologics in asthma","volume":"15","author":"Matsumoto-Sasaki","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2025.102375_bib60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12931-021-01733-9","article-title":"Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics","volume":"22","author":"Liu","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2025.102375_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2022.06.012","article-title":"Biologic use and outcomes among adults with severe asthma treated by US subspecialists","volume":"129","author":"Panettieri","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.pupt.2025.102375_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020200","article-title":"Biologics in severe eosinophilic asthma: three-year Follow-Up in a SANI single center","volume":"10","author":"Solidoro","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.pupt.2025.102375_bib63","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00273-2022","article-title":"Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study","volume":"8","author":"Frix","year":"2022","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.pupt.2025.102375_bib64","series-title":"Switching to Dupilumab from Other Biologics Without a Treatment Interval in Patients with Severe Asthma: a Multi-Center Retrospective Study","author":"Higo","year":"2023"},{"key":"10.1016\/j.pupt.2025.102375_bib65","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2025.102375_bib66","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMe1408614","article-title":"Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma","volume":"371","author":"Nair","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib67","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01511-2019","article-title":"The importance of real-life research in respiratory medicine: manifesto of the respiratory effectiveness group: endorsed by the international primary care respiratory group and the world allergy organization","volume":"54","author":"Roche","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2025.102375_bib68","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2025.102375_bib69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib70","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1159\/000525723","article-title":"Discontinuing omalizumab treatment in super-responder patients with allergic severe asthma: can the baseline total IgE level be used as a biological marker to decide discontinuing omalizumab treatment?","volume":"183","author":"Arslan","year":"2022","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.pupt.2025.102375_bib71","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4081\/mrm.2021.736","article-title":"Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study","volume":"16","author":"Tani","year":"2021","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106595","article-title":"Efficacy of mepolizumab in usual clinical practice and characteristics of responders","volume":"187","author":"Rodr\u00edguez-Garc\u00eda","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2025.102375_bib73","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \"Super-Responder\" to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2025.102375_bib74","article-title":"Real-world super-response to biologics in severe asthma: a French monocentric retrospective cohort study","author":"Val\u00e9ry","year":"2023","journal-title":"Respir. Med. Res."},{"key":"10.1016\/j.pupt.2025.102375_bib75","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.alit.2022.05.010","article-title":"Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis","volume":"71","author":"Hoshino","year":"2022","journal-title":"Allergol. Int."},{"key":"10.1016\/j.pupt.2025.102375_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9121822","article-title":"Switch from omalizumab to benralizumab in allergic patients with severe eosinophilic asthma: a real-life experience from Southern Italy","volume":"9","author":"Pelaia","year":"2021","journal-title":"Biomedicines"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455392500032X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455392500032X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:01:42Z","timestamp":1756900902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109455392500032X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":75,"alternative-id":["S109455392500032X"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2025.102375","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The era of multiple biologics: Is combination and switching an option in the management of severe asthma?","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2025.102375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102375"}}